Zimmer Holdings announced Thursday that it will acquire Biomet in a nearly $13.35 billion transaction that will provide it with a leading position in the $45 billion musculoskeletal industry.
The merger between the two Warsaw, IN–based orthopedic device makers is expected to close early next year pending customary closing conditions and regulatory approvals.
The $13.35 billion includes cash, stock, and the assumption of debt.
|Refresh your medical device industry knowledge at MD&M East, June 9–12, 2014 in New York City.|
Zimmer officials see enhanced innovation and cross-selling opportunities from the acquisition. Cash flows from operations are expected to increase by 1.5 times Zimmer's stand-alone estimates.
“We believe that current demographic and macroeconomic trends affecting the healthcare industry will reward companies that successfully partner with other key stakeholders to improve patient care in a cost-effective manner. … This combination is about achieving growth and cultivating best-in-class solutions,” David Dvorak, Zimmer president and CEO, said in a news release.
Dvorak also said: “We are equally committed to delivering quality products and outstanding clinical results and to legal and ethical behavior in the markets where we do business. And as companies focused almost exclusively in the musculoskeletal industry, we are passionate about orthopaedics and the related medical technology markets that we serve."
- Conformal Coatings for Tomorrow’s Medical Technologies - Webcast
- ISO80369 Standards Bring Changes to Medical Device Companies - Webcast
- Automation in Machining - Webcast
- How to Develop a Risk Based Biological Safety Evaluation Per New US FDA Guidance - Webcast
- 3 Tips for Successfully Launching an Outsourced Medical Device - Webcast
- When Do I Really Need to Perform an Ethylene Oxide Requalification? - Webcast